SRPT Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

22.105

Open

20.720

VWAP

21.53

Vol

2.30M

Mkt Cap

2.28B

Low

20.720

Amount

49.49M

EV/EBITDA(TTM)

Total Shares

104.99M

2.04B

EV/OCF(TTM)

P/S(TTM)

0.95

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

Events Timeline

(ET)

2026-03-25

16:30:00

Major Averages Rise on U.S. Iran Peace Plan

2026-03-25

12:10:00

U.S. Offers Iran 15-Point Peace Plan, Oil Prices Drop

2026-03-25

10:10:00

Leerink Analyst Says Sarepta siRNA Data is a Mixed Bag

2026-03-25

08:10:00

Sarepta Therapeutics Shares siRNA Clinical Results

News

6.0

03-26moomoo

SAREPTA THERAPEUTICS, INC.: DEUTSCHE BANK INCREASES TARGET PRICE FROM $12 TO $14

4.0

03-26moomoo

SAREPTA THERAPEUTICS INC: WEDBUSH INCREASES TARGET PRICE FROM $29 TO $35

4.0

03-26moomoo

SAREPTA THERAPEUTICS INC: CITIGROUP INCREASES TARGET PRICE FROM $9 TO $13

4.0

03-26moomoo

SAREPTA THERAPEUTICS INC: PIPER SANDLER INCREASES TARGET PRICE FROM $16 TO $23

9.5

03-25stocktwits

Sarepta's Promising Data Sparks Market Optimism

9.0

03-25stocktwits

SRPT Stock Sees Largest Daily Increase in Almost 8 Years Following Rare Muscle Disorders Study, Yet Wall Street Remains Skeptical

18 Analyst Rating

Wall Street analysts forecast SRPT stock price to rise

4 Buy

10 Hold

4 Sell

Hold

Current: 0.000

Low

5.00

Averages

20.80

High

45.00

Current: 0.000

Low

5.00

Averages

20.80

High

45.00

Wedbush

Outperform

maintain

$29 -> $35

AI Analysis

2026-03-26

Reason

Wedbush

Price Target

$29 -> $35

AI Analysis

2026-03-26

maintain

Outperform

Reason

Wedbush raised the firm's price target on Sarepta to $35 from $29 and keeps an Outperform rating on the shares after including SRP-1001 for facioscapulohumeral muscular dystrophy and SRP-1003 for myotonic dystrophy type 1 into valuation, based on positive preliminary data reported from the Phase 1/2 studies yesterday. Both SRP-1001 and SRP-1003 showed a strong safety profile with no dose limiting toxicities or treatment-related SAEs, as well as dose-dependent plasma exposure. Wedbush projects SRP-1001 and SRP-1003 to enter the U.S. market in 2031 and 2032, through accelerated approval pathway that other more advanced programs for the same indications have helped to established, with modest 20% and 10% probability of success, respectively. Despite the early stage of the programs, the firm sees the initial data as a critical step forward for Sarepta's siRNA portfolio to create significant value for the stock.

Deutsche Bank

Sell

maintain

$12 -> $14

2026-03-26

Reason

Deutsche Bank

Price Target

$12 -> $14

2026-03-26

maintain

Sell

Reason

Deutsche Bank raised the firm's price target on Sarepta to $14 from $12 and keeps a Sell rating on the shares. The company yesterday exported positive preliminary data for its ARWR-licensed siRNA assets, SRP-1001 and SRP-1003, which came in above investor expectations, the analyst tells investors in a research note. Deutsche, however, is surprised by the stock's 35% rally, given the small number of patients dosed, limited duration of treatment, lack of data from multiple ascending dose cohorts, lack of key biomarkers. The data could merit a stock move of 15%-20%, making the 35% rally overdone, contends the firm.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SRPT

Unlock Now

Valuation Metrics

The current forward P/E ratio for Sarepta Therapeutics Inc (SRPT.O) is 89.24, compared to its 5-year average forward P/E of 6.79. For a more detailed relative valuation and DCF analysis to assess Sarepta Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

6.79

Current PE

89.24

Overvalued PE

44.65

Undervalued PE

-31.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

4.35

Current EV/EBITDA

27.78

Overvalued EV/EBITDA

91.56

Undervalued EV/EBITDA

-82.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.30

Current PS

1.46

Overvalued PS

9.14

Undervalued PS

3.47

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

strongest stock for upside swing

Intellectia · 25 candidates

Price: >= $10.00Rsi Category: moderate, overboughtList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $25.00One Week Rise Prob: >= 65Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

ASST

Strive Inc

686.75M

ORKA

Oruka Therapeutics Inc

1.98B

PRAA

PRA Group Inc

684.85M

CAR

Avis Budget Group Inc

4.14B

FIGS

Figs Inc

2.54B

PTEN

Patterson-UTI Energy Inc

4.13B

was soll ich heute kaufen.

Intellectia · 12 candidates

Market Cap: >= 2.00BRegion: USThemes: BiotechMarket Cap Category: mid, largeRevenue 5yr Cagr: >= 0Weekly Average Turnover: >= 1,000,000List Exchange: XNYS, XNAS, XASEIs Optionable: True

Ticker

Name

Market Cap$

AMGN

Amgen Inc

185.02B

GILD

Gilead Sciences Inc

160.18B

VRTX

Vertex Pharmaceuticals Inc

117.00B

REGN

Regeneron Pharmaceuticals Inc

78.75B

BNTX

Biontech SE

29.61B

ILMN

Illumina Inc

23.30B

list of biotech stock

Intellectia · 11 candidates

Market Cap: >= 1000.00MThemes: BiotechBeta: LowRiskWeekly Average Turnover: >= 1,000,000Is Optionable: True

Ticker

Name

Market Cap$

AMGN

Amgen Inc

185.02B

GILD

Gilead Sciences Inc

160.18B

VRTX

Vertex Pharmaceuticals Inc

117.00B

REGN

Regeneron Pharmaceuticals Inc

78.75B

BNTX

Biontech SE

29.61B

BIIB

Biogen Inc

25.32B

show me onlybiostock

Intellectia · 19 candidates

Themes: BiotechWeekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

AMGN

Amgen Inc

185.02B

GILD

Gilead Sciences Inc

160.18B

VRTX

Vertex Pharmaceuticals Inc

117.00B

REGN

Regeneron Pharmaceuticals Inc

78.75B

BNTX

Biontech SE

29.61B

BIIB

Biogen Inc

25.32B

Whales Holding SRPT

Tang Capital Management, LLC

Voleon Capital Management LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Sarepta Therapeutics Inc (SRPT) stock price today?

The current price of SRPT is 21.76 USD — it has increased 6.25

What is Sarepta Therapeutics Inc (SRPT)'s business?

What is the price predicton of SRPT Stock?

Wall Street analysts forecast SRPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRPT is20.80 USD with a low forecast of 5.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Sarepta Therapeutics Inc (SRPT)'s revenue for the last quarter?

Sarepta Therapeutics Inc revenue for the last quarter amounts to 442.93M USD, decreased -32.73

What is Sarepta Therapeutics Inc (SRPT)'s earnings per share (EPS) for the last quarter?

Sarepta Therapeutics Inc. EPS for the last quarter amounts to -2.70 USD, decreased -304.55

How many employees does Sarepta Therapeutics Inc (SRPT). have?

Sarepta Therapeutics Inc (SRPT) has 835 emplpoyees as of April 01 2026.

What is Sarepta Therapeutics Inc (SRPT) market cap?

Today SRPT has the market capitalization of 2.28B USD.

SRPT Overview

SRPT Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding SRPT

Trading Trends

People Also Watch

Frequently Asked Questions

What is Sarepta Therapeutics Inc (SRPT) stock price today?

What is Sarepta Therapeutics Inc (SRPT)'s business?

What is the price predicton of SRPT Stock?

What is Sarepta Therapeutics Inc (SRPT)'s revenue for the last quarter?

What is Sarepta Therapeutics Inc (SRPT)'s earnings per share (EPS) for the last quarter?

How many employees does Sarepta Therapeutics Inc (SRPT). have?

What is Sarepta Therapeutics Inc (SRPT) market cap?